Table 3.
Summary of individual treatments utilized over the course of follow-up at MDACC for patients in this series.
| Treatments, side-effects and responses for patients included in this study | ||||||||
|---|---|---|---|---|---|---|---|---|
| Gender | Radiation | Chemotherapy | ||||||
| Received | Dose (Gy) | Side Effects | Response | Received | Regimen | Side Effects | Response | |
| F | Y | 143 | Skin sloughing | Progression | Y | CCNU, Adriamycin | Alopecia | Progression |
| M | N | -- | -- | -- | N | -- | -- | -- |
| F | Y | 55 | Otalgia | Progression | N | -- | -- | -- |
| M | Y | N/A | N/A | Progression | Y | VP-16, Cisplatin | N/A | Progression |
| F | Y | 68 | Mucositis | Progression | Y | DTIC, Adriamycin, Mesna, Ifosfamide | N/A | Progression |
| F | Y | N/A | N/A | Progression | Y | CDDP, VP-16 | None | Progression |
| F | Y | N/A | N/A | Regression | Y | N/A | N/A | Regression |
| M | Y | 90 | N/A | Progression | Y | CVAD | Febrile neutropenia, N/V | Stable |
| F | Y | 39 | N/A | N/A | Y | CVAD | N/A | N/A |
| M | Y | 60 | None | Progression | Y | Adriamycin, Cytoxan, VP-16, Cisplatin, FTI | None | Progression |
| F | N | -- | -- | -- | Y | CVAD | N/A | N/A |
| M | Y | N/A | N/A | Progression | N | -- | -- | -- |
| F | N | -- | -- | -- | N | -- | -- | -- |
| F | Y | N/A | N/A | Stable | N | -- | -- | -- |
| F | Y | N/A | N/A | Progression | Y | Taxol, Cytoxan, Adriamycin, DTIC | None | Stable |
| F | Y | N/A | N/A | Progression | N | -- | -- | -- |
| F | N | -- | -- | -- | N | -- | -- | -- |
| F | N | -- | -- | -- | N | -- | -- | -- |
| F | Y | N/A | Mucositis | Progression | Y | CVAD | Alopecia | Progression |
N/A implies the data are unknown, '-' implies the patients did not receive the therapy. (Summary of abbreviations: CCNU: Lomustine; VP-16: Etoposide; DTIC: Dacarbazine; CDDP: Cisplatin; CVAD: Cyclophosphamide, Vincristine, Doxorubicin, and Dacarbazine; FTI: Farnesyl transferase inhibitor; N/V: Nausea/Vomiting)